Drug Trial Radar · NCT06391931
A Multicenter, Open, Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Cipepofol Injection for General Anesthesia in Pediatric Patients Undergoing Elective Surgery
Last checked: Nov 19, 2026Latest source record: Jul 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
190
Actual
Start
Apr 7, 2024
Primary completion
Nov 6, 2024
Study completion Nov 28, 2024
Sponsor
- Lead sponsor
- Haisco Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 30, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 2 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multicenter, open, controlled, Phase III clinical study to evaluate the efficacy and safety of Cipepofol injection for general anesthesia in pediatric patients undergoing elective surgery
Conditions
- Anesthesia
Interventions
CipepofolDrug
0.6±0.2 mg/kg induce + 0.8 mg/kg/h maintain
PropofolDrug
3.0 mg/kg induce + 5.0 mg/kg/h maintain
Primary outcomes
What the sponsor says the trial is designed to measure.
- Success rate of anesthesiaTime frame: 24 hours after the end of surgery
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.